Design characteristics that influence attrition in geriatric antidepressant trials

Meta-analysis

Moonseong Heo, Eros Papademetriou, Barnett S. Meyers

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To identify study-level and treatment group-level characteristics that are associated with attrition in antidepressant trials for the depressed elderly. Methods: This meta-analysis used 68 published antidepressant randomized trials for the elderly depressed. Study-level and treatment group-level variables were extracted. The former consisted of: use of placebo arm, number of arms, unbalanced treatment allocation, year conducted, study duration, study location, number of centers, and patient pool. The latter consisted of: assigned treatments, baseline mean Hamilton Depression Rating Scale (HDRS), baseline mean age, gender ratio, attrition size, and sample size. Univariate logistic regressions with attrition as the dependent variable were applied, followed by application of a forward stepwise selection method for identification of independent attrition correlates. Results: The 68 studies had a total of 153 treatment groups and 8,385 subjects. Among them, 2,287 subjects were terminated early, resulting in an overall 27.3% attrition rate. The stepwise results showed that higher attrition was significantly associated with active antidepressant groups as opposed to placebo groups, higher baseline HDRS, smaller sample size, unbalanced allocation of treatments, longer duration, and studies conducted in USA. Conclusions: The attrition in geriatric antidepressant trials can be affected by study and group-level design characteristics that include severity of depression symptoms and active treatments among others.

Original languageEnglish (US)
Pages (from-to)990-1001
Number of pages12
JournalInternational Journal of Geriatric Psychiatry
Volume24
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Geriatrics
Antidepressive Agents
Meta-Analysis
Sample Size
Therapeutics
Placebos
Logistic Models

Keywords

  • Antidepressants
  • Attrition
  • Elderly
  • Placebo
  • RCT

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Design characteristics that influence attrition in geriatric antidepressant trials : Meta-analysis. / Heo, Moonseong; Papademetriou, Eros; Meyers, Barnett S.

In: International Journal of Geriatric Psychiatry, Vol. 24, No. 9, 09.2009, p. 990-1001.

Research output: Contribution to journalArticle

@article{ffea071c7c364c748f749c96a49bed3a,
title = "Design characteristics that influence attrition in geriatric antidepressant trials: Meta-analysis",
abstract = "Objective: To identify study-level and treatment group-level characteristics that are associated with attrition in antidepressant trials for the depressed elderly. Methods: This meta-analysis used 68 published antidepressant randomized trials for the elderly depressed. Study-level and treatment group-level variables were extracted. The former consisted of: use of placebo arm, number of arms, unbalanced treatment allocation, year conducted, study duration, study location, number of centers, and patient pool. The latter consisted of: assigned treatments, baseline mean Hamilton Depression Rating Scale (HDRS), baseline mean age, gender ratio, attrition size, and sample size. Univariate logistic regressions with attrition as the dependent variable were applied, followed by application of a forward stepwise selection method for identification of independent attrition correlates. Results: The 68 studies had a total of 153 treatment groups and 8,385 subjects. Among them, 2,287 subjects were terminated early, resulting in an overall 27.3{\%} attrition rate. The stepwise results showed that higher attrition was significantly associated with active antidepressant groups as opposed to placebo groups, higher baseline HDRS, smaller sample size, unbalanced allocation of treatments, longer duration, and studies conducted in USA. Conclusions: The attrition in geriatric antidepressant trials can be affected by study and group-level design characteristics that include severity of depression symptoms and active treatments among others.",
keywords = "Antidepressants, Attrition, Elderly, Placebo, RCT",
author = "Moonseong Heo and Eros Papademetriou and Meyers, {Barnett S.}",
year = "2009",
month = "9",
doi = "10.1002/gps.2211",
language = "English (US)",
volume = "24",
pages = "990--1001",
journal = "International Journal of Geriatric Psychiatry",
issn = "0885-6230",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Design characteristics that influence attrition in geriatric antidepressant trials

T2 - Meta-analysis

AU - Heo, Moonseong

AU - Papademetriou, Eros

AU - Meyers, Barnett S.

PY - 2009/9

Y1 - 2009/9

N2 - Objective: To identify study-level and treatment group-level characteristics that are associated with attrition in antidepressant trials for the depressed elderly. Methods: This meta-analysis used 68 published antidepressant randomized trials for the elderly depressed. Study-level and treatment group-level variables were extracted. The former consisted of: use of placebo arm, number of arms, unbalanced treatment allocation, year conducted, study duration, study location, number of centers, and patient pool. The latter consisted of: assigned treatments, baseline mean Hamilton Depression Rating Scale (HDRS), baseline mean age, gender ratio, attrition size, and sample size. Univariate logistic regressions with attrition as the dependent variable were applied, followed by application of a forward stepwise selection method for identification of independent attrition correlates. Results: The 68 studies had a total of 153 treatment groups and 8,385 subjects. Among them, 2,287 subjects were terminated early, resulting in an overall 27.3% attrition rate. The stepwise results showed that higher attrition was significantly associated with active antidepressant groups as opposed to placebo groups, higher baseline HDRS, smaller sample size, unbalanced allocation of treatments, longer duration, and studies conducted in USA. Conclusions: The attrition in geriatric antidepressant trials can be affected by study and group-level design characteristics that include severity of depression symptoms and active treatments among others.

AB - Objective: To identify study-level and treatment group-level characteristics that are associated with attrition in antidepressant trials for the depressed elderly. Methods: This meta-analysis used 68 published antidepressant randomized trials for the elderly depressed. Study-level and treatment group-level variables were extracted. The former consisted of: use of placebo arm, number of arms, unbalanced treatment allocation, year conducted, study duration, study location, number of centers, and patient pool. The latter consisted of: assigned treatments, baseline mean Hamilton Depression Rating Scale (HDRS), baseline mean age, gender ratio, attrition size, and sample size. Univariate logistic regressions with attrition as the dependent variable were applied, followed by application of a forward stepwise selection method for identification of independent attrition correlates. Results: The 68 studies had a total of 153 treatment groups and 8,385 subjects. Among them, 2,287 subjects were terminated early, resulting in an overall 27.3% attrition rate. The stepwise results showed that higher attrition was significantly associated with active antidepressant groups as opposed to placebo groups, higher baseline HDRS, smaller sample size, unbalanced allocation of treatments, longer duration, and studies conducted in USA. Conclusions: The attrition in geriatric antidepressant trials can be affected by study and group-level design characteristics that include severity of depression symptoms and active treatments among others.

KW - Antidepressants

KW - Attrition

KW - Elderly

KW - Placebo

KW - RCT

UR - http://www.scopus.com/inward/record.url?scp=70350757993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350757993&partnerID=8YFLogxK

U2 - 10.1002/gps.2211

DO - 10.1002/gps.2211

M3 - Article

VL - 24

SP - 990

EP - 1001

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - 9

ER -